Why carry out this study?

Allergic conjunctivitis is a highly prevalent disorder of the ocular conjunctive which can greatly affect quality of life.

Bilastine is an efficient and safe antihistamine that has been used to reduce symptoms and signs of allergic conjunctivitis. The pharmacokinetics and safety of a recently developed preservative-free, ophthalmic formulation of bilastine were investigated.

What was learned from the study?

Bilastine once-daily ophthalmic formulation 6 mg/mL is absorbed into the bloodstream in low amounts by the ophthalmic route.

The ophthalmic formulation of bilastine showed a good safety profile after multiple dose administration.

Further controlled clinical trials are warranted to evaluate the efficacy and safety of ophthalmic bilastine in the treatment of allergic conjunctivitis.